Looming regulation of faecal microbiota transplantation (FMT) must not stifle clinical trials and must be flexible to accommodate rapidly evolving treatment options, gastroenterologists say. The TGA is consulting with gastroenterologists over regulation of material used for FMT, which is currently recommended as treatment for C. difficile and may have a role in treating ulcerative colitis. Currently, ...
Will regulation stifle the rapidly evolving field of FMT?
By Tessa Hoffman
8 Nov 2018